|
JPS5992710A
(ja)
*
|
1982-11-16 |
1984-05-29 |
関西電力株式会社 |
直接水冷線路の立坑部の布設方法
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
PL1759001T3
(pl)
|
2004-04-21 |
2011-09-30 |
Alexion Pharma Inc |
Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
|
|
AU2006272555B2
(en)
|
2005-07-25 |
2012-03-08 |
Aptevo Research And Development Llc |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
GB0614780D0
(en)
*
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
CA2680792A1
(en)
*
|
2007-03-15 |
2008-09-18 |
Biogen Idec Ma Inc. |
Treatment of autoimmune disorders
|
|
SI2185589T1
(sl)
|
2007-06-01 |
2016-04-29 |
University Of Maryland Baltimore |
Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
|
|
WO2009023386A2
(en)
*
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
TW200944231A
(en)
*
|
2007-11-30 |
2009-11-01 |
Glaxo Group Ltd |
Antigen-binding constructs
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
EP2344546A1
(en)
*
|
2008-10-13 |
2011-07-20 |
Zymogenetics, Inc. |
Single chain fc type iii interferons and methods of using same
|
|
WO2010065578A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Leukosight Inc. |
POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
|
|
CN102245771B
(zh)
|
2008-12-16 |
2013-04-10 |
诺瓦提斯公司 |
酵母展示系统
|
|
JP5906090B2
(ja)
|
2009-02-17 |
2016-04-20 |
コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ |
癌の診断のための方法およびキットならびに治療価の推定
|
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
|
JP2013507926A
(ja)
*
|
2009-10-14 |
2013-03-07 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
|
|
TW201120210A
(en)
*
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
|
CA3040276A1
(en)
*
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
US11536713B2
(en)
|
2009-12-25 |
2022-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
|
|
SG10201503351RA
(en)
|
2010-01-19 |
2015-06-29 |
Harvard College |
Engineered Opsonin for Pathogen Detection and Treatment
|
|
AU2011215684A1
(en)
*
|
2010-02-12 |
2012-08-30 |
Research Corporation Technologies |
Multimeric proteins comprising immunoglobulin constant domains
|
|
WO2011117653A1
(en)
*
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Disulfide stabilized dvd-lg molecules
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
ES2912934T3
(es)
|
2010-04-16 |
2022-05-30 |
Biogen Ma Inc |
Anticuerpos anti VLA-4
|
|
PT2591006T
(pt)
*
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
WO2012016073A2
(en)
|
2010-07-28 |
2012-02-02 |
Gliknik Inc. |
Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
SG189302A1
(en)
|
2010-10-06 |
2013-05-31 |
Pharmalogicals Res Pte Ltd |
Cancer stem cell population and method for production thereof
|
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
JP6055779B2
(ja)
|
2010-12-27 |
2016-12-27 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
ナトリウム利尿ペプチドを含む組成物およびその使用方法
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
EA201892619A1
(ru)
*
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2013012733A1
(en)
*
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
CA3149018A1
(en)
|
2011-07-18 |
2013-01-24 |
President And Fellows Of Harvard College |
Engineered microbe-targeting molecules and uses thereof
|
|
PH12014500220A1
(en)
*
|
2011-07-27 |
2019-03-22 |
Glaxo Group Ltd |
Anti-vegf single variable domains fused to fc domains
|
|
US9556281B2
(en)
|
2011-08-15 |
2017-01-31 |
The University Of Chicago |
Compositions and methods related to antibodies to staphylococcal protein A
|
|
MY167125A
(en)
|
2011-08-17 |
2018-08-13 |
Glaxo Group Ltd |
Modified proteins and peptides
|
|
WO2013033008A2
(en)
*
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
JP6077997B2
(ja)
|
2011-09-07 |
2017-02-08 |
中外製薬株式会社 |
癌幹細胞の分離
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
DK2760471T3
(en)
|
2011-09-30 |
2017-05-08 |
Dana Farber Cancer Inst Inc |
THERAPEUTIC PEPTIDES
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SI2766397T1
(sl)
*
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
|
EP3603671A3
(en)
*
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
US8961971B2
(en)
|
2011-12-22 |
2015-02-24 |
Development Center For Biotechnology |
Bispecific T-cell activator antibody
|
|
EP3539982B1
(en)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
CN104159922B
(zh)
*
|
2012-01-10 |
2018-03-02 |
比奥根Ma公司 |
对转运治疗性分子穿过血脑屏障的增强
|
|
EP4624490A3
(en)
|
2012-02-09 |
2025-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
MX2014009565A
(es)
*
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
CA2865158C
(en)
|
2012-02-24 |
2022-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
|
|
USRE49477E1
(en)
*
|
2012-04-20 |
2023-03-28 |
Thomas Jefferson University |
Engineered antibody for inhibition of fibrosis
|
|
US9969794B2
(en)
|
2012-05-10 |
2018-05-15 |
Visterra, Inc. |
HA binding agents
|
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
JP6154895B2
(ja)
*
|
2012-06-07 |
2017-06-28 |
デューク ユニバーシティー |
ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
|
|
AU2013270682A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Procoagulant compounds
|
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
ES2597228T3
(es)
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
|
WO2014004780A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Bristol-Myers Squibb Company |
Methods for reducing glycoprotein aggregation
|
|
PL3434695T3
(pl)
*
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Ulepszona immunoterapia
|
|
KR20150058236A
(ko)
|
2012-08-20 |
2015-05-28 |
글리크닉 인코포레이티드 |
항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
|
|
JO3462B1
(ar)
*
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
CA2888519C
(en)
*
|
2012-10-17 |
2023-02-21 |
Liverpool School Of Tropical Medicine |
Immunomodulatory proteins
|
|
US20150322152A1
(en)
*
|
2012-11-30 |
2015-11-12 |
Institut Pasteur |
Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
|
|
US10487155B2
(en)
*
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
*
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
TWI682941B
(zh)
*
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
|
RS61387B2
(sr)
|
2013-02-15 |
2024-06-28 |
Bioverativ Therapeutics Inc |
Gen optimizovanog faktora viii
|
|
SG11201506451UA
(en)
*
|
2013-03-06 |
2015-09-29 |
Merrimack Pharmaceuticals Inc |
Anti-c-met tandem fc bispecific antibodies
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US9289461B2
(en)
|
2013-03-15 |
2016-03-22 |
Mead Johnson Nutrition Company |
Reducing the risk of autoimmune disease
|
|
US9138455B2
(en)
|
2013-03-15 |
2015-09-22 |
Mead Johnson Nutrition Company |
Activating adiponectin by casein hydrolysate
|
|
US8889633B2
(en)
|
2013-03-15 |
2014-11-18 |
Mead Johnson Nutrition Company |
Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
|
|
US9345741B2
(en)
|
2013-03-15 |
2016-05-24 |
Mead Johnson Nutrition Company |
Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
|
|
US9345727B2
(en)
|
2013-03-15 |
2016-05-24 |
Mead Johnson Nutrition Company |
Nutritional compositions containing a peptide component and uses thereof
|
|
US9352020B2
(en)
|
2013-03-15 |
2016-05-31 |
Mead Johnson Nutrition Company |
Reducing proinflammatory response
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
*
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10551379B2
(en)
|
2013-03-15 |
2020-02-04 |
President And Fellows Of Harvard College |
Methods and compositions for improving detection and/or capture of a target entity
|
|
WO2014144791A2
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
EP3848045A1
(en)
|
2013-05-21 |
2021-07-14 |
President and Fellows of Harvard College |
Engineered heme-binding compositions and uses thereof
|
|
KR101654890B1
(ko)
*
|
2013-07-10 |
2016-09-07 |
한국과학기술원 |
면역글로불린 g에 대한 리피바디 및 그 용도
|
|
FR3012453B1
(fr)
|
2013-10-31 |
2015-11-13 |
Lab Francais Du Fractionnement |
Proteine chimerique dans le traitement de l’amylose
|
|
MX371187B
(es)
|
2013-12-06 |
2020-01-22 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos.
|
|
US10513546B2
(en)
|
2013-12-18 |
2019-12-24 |
President And Fellows Of Harvard College |
CRP capture/detection of gram positive bacteria
|
|
CN106103476B
(zh)
|
2013-12-24 |
2020-11-27 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
|
US10654933B2
(en)
*
|
2013-12-27 |
2020-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying antibody having low isoelectric point
|
|
CA2938066C
(en)
*
|
2014-02-02 |
2025-05-06 |
Medimmune Limited |
CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A
|
|
CN106068274A
(zh)
|
2014-03-05 |
2016-11-02 |
Ucb生物制药私人有限公司 |
多聚体Fc蛋白
|
|
EP3116903A2
(en)
|
2014-03-14 |
2017-01-18 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CN107172880B
(zh)
*
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
SG10201913507SA
(en)
|
2014-05-02 |
2020-02-27 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
CN106456734A
(zh)
*
|
2014-05-29 |
2017-02-22 |
免疫医疗有限责任公司 |
Ox40l融合蛋白及其用途
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
|
MX2016017288A
(es)
*
|
2014-07-16 |
2017-06-27 |
Genentech Inc |
Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
|
|
CA2964895A1
(en)
*
|
2014-10-20 |
2016-04-28 |
The Scripps Research Institute |
Proximity based methods for selection of binding partners
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
CN104403004B
(zh)
*
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
JP6787894B2
(ja)
|
2014-12-05 |
2020-11-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
組換えアルカリホスファターゼを用いた発作の処置
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
US9767555B2
(en)
*
|
2015-01-05 |
2017-09-19 |
Case Western Reserve University |
Disease characterization from fused pathology and radiology data
|
|
CA2973883A1
(en)
|
2015-01-28 |
2016-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
|
MA41459A
(fr)
*
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
MX386491B
(es)
|
2015-03-09 |
2025-03-18 |
argenx BV |
Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
PL3283524T3
(pl)
*
|
2015-04-17 |
2023-06-12 |
Amgen Research (Munich) Gmbh |
Konstrukty biswoistego przeciwciała dla cdh3 i cd3
|
|
AU2016274890B2
(en)
*
|
2015-06-12 |
2022-02-10 |
Ubi Pharma Inc |
Immunoglobulin fusion proteins and uses thereof
|
|
WO2016207402A1
(en)
|
2015-06-26 |
2016-12-29 |
Institute For Research In Biomedicine |
Proteins comprising a mutated lair-1 fragment and uses thereof
|
|
IL309260B2
(en)
|
2015-07-24 |
2025-01-01 |
Gliknik Inc |
Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
*
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
*
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
US10435457B2
(en)
|
2015-08-06 |
2019-10-08 |
President And Fellows Of Harvard College |
Microbe-binding molecules and uses thereof
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
JP6993961B2
(ja)
|
2015-08-17 |
2022-01-14 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
アルカリホスファターゼの製造
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
MY195059A
(en)
|
2015-09-23 |
2023-01-05 |
Regeneron Pharma |
Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
|
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
|
|
WO2017059878A1
(en)
|
2015-10-07 |
2017-04-13 |
Humabs Biomed Sa |
Antibodies that potently neutralize hepatitis b virus and uses thereof
|
|
EP3368062A4
(en)
|
2015-10-30 |
2019-07-03 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
|
|
ES2909973T3
(es)
*
|
2015-11-04 |
2022-05-10 |
Hope City |
Receptores quiméricos para el antígeno que se dirigen a HER2
|
|
WO2017083627A1
(en)
|
2015-11-13 |
2017-05-18 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
WO2017096124A1
(en)
*
|
2015-12-03 |
2017-06-08 |
National Health Research Institutes |
Heterodimeric vascular endothelial growth factor and use thereof
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
|
AR107582A1
(es)
*
|
2016-02-03 |
2018-05-16 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
|
CA3015347A1
(en)
|
2016-02-24 |
2017-08-31 |
Visterra, Inc. |
Formulations of antibody molecules to influenza virus
|
|
US12391759B2
(en)
|
2016-03-02 |
2025-08-19 |
Momenta Pharmaceuticals, Inc. |
Methods related to engineered Fc constructs
|
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
|
WO2017172853A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Ab Biosciences, Inc. |
Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
|
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
KR20180125979A
(ko)
|
2016-04-01 |
2018-11-26 |
알렉시온 파마슈티칼스, 인코포레이티드 |
알칼리성 포스파타아제로 근육 약화의 치료
|
|
US10723857B1
(en)
*
|
2016-04-15 |
2020-07-28 |
United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration |
Polyimide aerogels with reduced shrinkage from isothermal aging
|
|
KR101685532B1
(ko)
*
|
2016-04-26 |
2016-12-13 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질
|
|
IL309293A
(en)
|
2016-05-23 |
2024-02-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods relating to engineered FC constructs
|
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
|
CA3026420A1
(en)
|
2016-06-07 |
2017-12-14 |
Gliknik Inc. |
Cysteine-optimized stradomers
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
MA45554A
(fr)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
Fusions de binucléase optimisées.
|
|
WO2018010789A1
(en)
|
2016-07-13 |
2018-01-18 |
Humabs Biomed Sa |
Novel antibodies specifically binding to zika virus epitopes and uses thereof
|
|
CN106191072A
(zh)
*
|
2016-08-04 |
2016-12-07 |
沈沭彤 |
重组人源嵌合GcFc基因片段及融合蛋白
|
|
JP7018933B2
(ja)
|
2016-08-18 |
2022-02-14 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
気管気管支軟化症の治療方法
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
BR112019009495A2
(pt)
|
2016-12-09 |
2019-08-06 |
Gliknik Inc |
métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
|
|
BR112019009484A2
(pt)
|
2016-12-09 |
2019-07-30 |
Gliknik Inc |
otimização de fabricação de gl-2045, um stradomer multimerizador
|
|
US20200031895A1
(en)
|
2016-12-16 |
2020-01-30 |
Biogen Ma Inc. |
Stabilized proteolytically activated growth differentiation factor 11
|
|
CN110650748B
(zh)
|
2017-01-06 |
2024-01-02 |
动量制药公司 |
与经工程改造的Fc构建体相关的组合物和方法
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
KR20190129058A
(ko)
|
2017-03-31 |
2019-11-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
|
|
EP3612562A2
(en)
|
2017-04-19 |
2020-02-26 |
Institute for Research in Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
|
EP3630843A2
(en)
|
2017-05-24 |
2020-04-08 |
ALS Therapy Development Institute |
Therapeutic anti-cd40 ligand antibodies
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019024979A1
(en)
|
2017-07-31 |
2019-02-07 |
Institute For Research In Biomedicine |
FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
|
|
MX2020001593A
(es)
|
2017-08-09 |
2020-07-13 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y usos de las mismas.
|
|
AU2018318440A1
(en)
*
|
2017-08-15 |
2020-02-13 |
Kindred Biosciences, Inc. |
IgG Fc variants for veterinary use
|
|
KR20210029298A
(ko)
*
|
2017-08-16 |
2021-03-15 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
|
|
CN111315767B
(zh)
|
2017-08-22 |
2025-03-18 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
|
WO2019042555A1
(en)
|
2017-08-31 |
2019-03-07 |
Humabs Biomed Sa |
MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MA51032A
(fr)
|
2017-12-08 |
2021-03-17 |
Argenx Bvba |
Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
CN111448217A
(zh)
|
2017-12-22 |
2020-07-24 |
阿根思公司 |
双特异性抗原结合构建体
|
|
US20210038744A1
(en)
|
2018-02-01 |
2021-02-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
WO2019190752A1
(en)
|
2018-03-30 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of glycoproteins
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
CN112867394B9
(zh)
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
JP7486437B2
(ja)
|
2018-06-08 |
2024-05-17 |
アルジェニクス ビーブイ |
免疫性血小板減少症を治療する組成物及び方法
|
|
JP2021526026A
(ja)
|
2018-06-08 |
2021-09-30 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
翻訳後修飾が低減したペプチドリンカー
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
|
WO2020033867A2
(en)
|
2018-08-10 |
2020-02-13 |
Alexion Pharmaceuticals, Inc. |
Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
|
|
ES3009025T3
(en)
|
2018-08-31 |
2025-03-25 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
|
|
KR20210079278A
(ko)
|
2018-09-06 |
2021-06-29 |
시다라 세라퓨틱스, 인코포레이티드 |
바이러스 감염의 치료를 위한 조성물 및 방법
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
CA3121786A1
(en)
|
2018-12-06 |
2020-06-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor ix
|
|
SI3898668T1
(sl)
|
2018-12-19 |
2024-02-29 |
Humabs Biomed Sa |
Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
|
|
PT4285929T
(pt)
|
2018-12-20 |
2026-01-02 |
Humabs Biomed Sa |
Terapêutica de combinação contra o vhb
|
|
SG11202108655TA
(en)
|
2019-02-15 |
2021-09-29 |
Univ Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
EP3946613A1
(en)
|
2019-03-25 |
2022-02-09 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
WO2020215010A1
(en)
|
2019-04-17 |
2020-10-22 |
Codiak Biosciences, Inc. |
Compositions of exosomes and aav
|
|
WO2020221451A1
(en)
|
2019-04-30 |
2020-11-05 |
Humabs Biomed Sa |
Antibodies binding to plasmodium circumsporozoite protein and uses thereof
|
|
BR112021024632A2
(pt)
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
|
|
EP3757127A1
(en)
|
2019-06-28 |
2020-12-30 |
Institute for Research in Biomedicine |
Deimmunized antibodies binding to alpha-4 integrin and uses thereof
|
|
EP3999544A4
(en)
*
|
2019-07-19 |
2023-08-09 |
Wuxi Xdc Singapore Private Limited |
POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
|
|
JP7762645B2
(ja)
*
|
2019-08-22 |
2025-10-30 |
シダラ セラピューティクス インコーポレーテッド |
バリアントｆｃドメイン及びその使用
|
|
US20220380441A1
(en)
|
2019-08-29 |
2022-12-01 |
Vir Biotechnology, Inc. |
Antibody compositions and methods for treating hepatitis b virus infection
|
|
TWI861205B
(zh)
|
2019-09-06 |
2024-11-11 |
美商席達拉醫療有限公司 |
用於治療病毒感染之組合物及方法
|
|
US12528882B2
(en)
|
2019-09-13 |
2026-01-20 |
The University Of Chicago |
Methods and compositions for treating staphylococcal infections
|
|
JP7803014B2
(ja)
|
2019-09-30 |
2026-01-21 |
バイオベラティブ セラピューティクス インコーポレイテッド |
レンチウイルスベクター製剤
|
|
WO2021089748A2
(en)
*
|
2019-11-06 |
2021-05-14 |
Amgen Research (Munich) Gmbh |
Multitargeting antigen-binding molecules for use in proliferative diseases
|
|
CA3161266A1
(en)
|
2019-12-09 |
2021-06-17 |
Alexion Pharmaceuticals, Inc. |
Alkaline phosphatase polypeptides and methods of use thereof
|
|
MX2022007207A
(es)
|
2019-12-11 |
2022-07-12 |
Visterra Inc |
Composiciones y metodos para tratar y prevenir la influenza.
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
JP2023537565A
(ja)
|
2020-06-24 |
2023-09-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
|
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
|
US12611447B2
(en)
|
2020-09-04 |
2026-04-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating bone mineralization disorders
|
|
BR112023008317A2
(pt)
|
2020-11-02 |
2024-02-06 |
Attralus Inc |
Proteínas de fusão sap fc e métodos de uso
|
|
JP2023552846A
(ja)
|
2020-12-08 |
2023-12-19 |
フマブス バイオメッド エスアー |
メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用
|
|
WO2022122788A1
(en)
|
2020-12-09 |
2022-06-16 |
Institute For Research In Biomedicine |
Multispecific antibodies against severe acute respiratory syndrome coronavirus 2
|
|
WO2022161598A1
(en)
|
2021-01-26 |
2022-08-04 |
Eth Zurich |
Antibodies broadly targeting coronaviruses and uses thereof
|
|
JP2024504167A
(ja)
|
2021-01-26 |
2024-01-30 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
|
|
WO2022162012A2
(en)
|
2021-01-26 |
2022-08-04 |
Eth Zurich |
Antibodies broadly targeting coronaviruses and uses thereof
|
|
AU2022218782B2
(en)
|
2021-02-12 |
2026-06-25 |
Alexion Pharmaceuticals, Inc. |
Alkaline phosphatase polypeptides and methods of use thereof
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
CA3172265A1
(en)
|
2021-03-10 |
2022-09-15 |
Dimitri BIELI |
Antibodies against tdp-43 and methods of using the same
|
|
CN113234168B
(zh)
*
|
2021-06-04 |
2022-09-13 |
浙江大学 |
一种融合蛋白、基因及应用
|
|
CN113406320B
(zh)
*
|
2021-08-18 |
2021-11-02 |
南京立顶医疗科技有限公司 |
基于重组基因工程抗体和微球的定向偶联方法及应用
|
|
IL311003A
(en)
|
2021-08-25 |
2024-04-01 |
Denali Therapeutics Inc |
Anti-2HER antibodies and methods of using them
|
|
CN118139879A
(zh)
|
2021-09-07 |
2024-06-04 |
生物医学研究院 |
结合破伤风毒素的抗体及其用途
|
|
CN118201961A
(zh)
*
|
2021-09-16 |
2024-06-14 |
Gt生物制药公司 |
Pd-l1靶向融合蛋白及其使用方法
|
|
MX2024007806A
(es)
|
2022-01-17 |
2024-07-04 |
argenx BV |
Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos.
|
|
KR20240151809A
(ko)
|
2022-02-21 |
2024-10-18 |
아르젠엑스 비브이 |
Fcrn 길항제를 사용하여 근염을 치료하는 방법
|
|
WO2023213400A1
(en)
|
2022-05-05 |
2023-11-09 |
Institute For Research In Biomedicine |
Antibodies against chemokines, method for identifying said antibodies and uses thereof
|
|
CA3170616A1
(en)
|
2022-05-18 |
2023-11-18 |
Natascha WUILLEMIN |
Anti-allergen antibodies and uses thereof
|
|
KR20250037789A
(ko)
|
2022-06-15 |
2025-03-18 |
아르젠엑스 비브이 |
Fcrn/항원-결합 분자 및 사용 방법
|
|
AR130995A1
(es)
|
2022-11-07 |
2025-02-05 |
argenx BV |
Métodos para el tratamiento de nefropatías membranosas primarias mediante el uso de antagonistas de fcrn
|
|
WO2024114906A1
(en)
|
2022-11-30 |
2024-06-06 |
Mabylon Ag |
Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
|
|
EP4630444A1
(en)
|
2022-12-08 |
2025-10-15 |
CSL Behring LLC |
Dissociable envelope binding proteins and uses thereof
|
|
WO2024147074A1
(en)
|
2023-01-06 |
2024-07-11 |
argenx BV |
Methods for treating pots using fcrn antagonists
|
|
CN120659623A
(zh)
|
2023-01-12 |
2025-09-16 |
阿根思有限公司 |
用于使用fcrn拮抗剂治疗原发性干燥综合征的方法
|
|
TW202525336A
(zh)
|
2023-03-14 |
2025-07-01 |
比利時商阿根思公司 |
對經FcRn拮抗劑治療之個體進行疫苗接種的方法
|
|
WO2024251358A1
(en)
|
2023-06-07 |
2024-12-12 |
Mabylon Ag |
Anti-allergen antibodies and uses thereof
|
|
IL325970A
(en)
|
2023-07-16 |
2026-03-01 |
argenx BV |
Methods for treating chronic inflammatory demyelinating polyneuropathy
|
|
EP4762080A1
(en)
*
|
2023-08-14 |
2026-06-24 |
The Bionics Institute of Australia |
A fusion protein
|
|
US20250101111A1
(en)
|
2023-09-07 |
2025-03-27 |
argenx BV |
Fcrn antagonists and methods of use
|
|
AU2024386429A1
(en)
|
2023-11-22 |
2026-05-21 |
Mabylon Ag |
Multispecific anti-allergen antibodies and uses thereof
|
|
AU2023474055A1
(en)
|
2023-11-23 |
2026-06-04 |
Mabylon Ag |
Multispecific anti-allergen antibodies and uses thereof
|
|
GB202318512D0
(en)
|
2023-12-04 |
2024-01-17 |
argenx BV |
Methods of determining potency
|
|
WO2025133694A1
(en)
|
2023-12-20 |
2025-06-26 |
argenx BV |
Fcrn/hsa-binding molecules and methods of use
|
|
US12698309B2
(en)
*
|
2024-08-01 |
2026-08-04 |
Twilight Bioscience, Inc. |
HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use
|
|
WO2026125663A2
(en)
|
2024-12-11 |
2026-06-18 |
Mabylon Ag |
Anti-allergen antibodies and uses thereof
|
|
WO2026150085A1
(en)
|
2025-01-10 |
2026-07-16 |
argenx BV |
Igg-binding molecules and methods of use thereof
|